Find your next M&A target

Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.

Project details

Japanese biopharmaceutical start-up seeks about USD 10 million B-round financing

Project region Japan
Industry Pharmeceuticals & Chemical
Total value of the target N/A
Expected target net rate of return after deducting all taxes and fees N/A
Validity period of pending order 365

CONTACT ADVISOR

  • Simon Laube

    Simon Laube

    Senior Associate, International Business Advisory

Project highlights DNA & RNA editing - technology licencing
Project description

The Japanese company develops DNA and RNA editing technology in the field of innovative medicines and chemical medicines, whose intellectual property assets may be granted rights to others under a licence, sublicence or other contract. The company's core is RNA-PPR technology. Its current products include repetitive motif RNA control platform, RNA splicing control platform and protein translation activation platform. The company seeks about USD 10 million (JPY 13 billion) B-round financing.

Enquire for more information about our services, and how we can help solve challenges for your organization

Contact Us
The code is case-sensitive